Example searches

CLDX Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Company profile

Ticker
CLDX
Exchange
NASDAQ
Website
www.celldex.com
CEO
Anthony S. Marucci
Employees
Incorporated in
Delaware
Location
New Jersey
Fiscal year end
Dec 31
Sector
Health Technology > Medical Specialties
Industry (SEC)
In Vitro & In Vivo Diagnostic Substances
IDEXX Laboratories • Lantheus • Quidel • Neogen • Meridian Bioscience • Myriad Genetics • Oxford Immunotec Global • Achieve Life Sciences • Intellia Therapeutics • Immunomedics ...
Former names
Avant Immunotherapeutics Inc, T Cell Sciences Inc
SEC CIK
0000744218
Corporate docs
IRS number
133191702

CLDX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 May 20
9 Jul 20
31 Dec 20

News

Company financial data Financial data

Chart CLDX financial data
Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 2.73M 887K 546K 715K
Net income -12.63M -10.45M -11.41M -11.78M
Diluted EPS -0.73 -0.64 -0.75 -0.84
Net profit margin -463% -1178% -2090% -1647%
Operating income -12.87M -12.99M -11.84M -12.26M
Net change in cash 11.49M -5.35M -3.16M -11.79M
Cash on hand 22.72M 11.23M 16.59M 19.74M
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 3.57M 9.54M 12.74M 6.79M
Net income -50.88M -151.18M -93.03M -128.53M
Diluted EPS -3.51 -14.48 -10.86 -18.99
Net profit margin -1424% -1585% -730% -1894%
Operating income -55.03M -156.44M -121.53M -132.92M
Net change in cash 0 -13.08M -18.15M -29.65M
Cash on hand 11.23M 11.23M 24.31M 42.46M
Cost of revenue 100K 700K 700K 1.6M

Financial data from company earnings reports

Recent insider trades

CLDX insider ownership history Insider history
Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
18 Jun 20 Shoos Karen L. NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Penner Harry JR NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Pepin Ronald Incentive Stock Option Common Stock Grant Aquire A No 10.38 14,400 149.47K 14,400
18 Jun 20 Wright Richard M. Incentive Stock Option Common Stock Grant Aquire A No 10.38 42,000 435.96K 42,000
18 Jun 20 Young Diane C. Incentive Stock Option Common Stock Grant Aquire A No 10.38 72,000 747.36K 72,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2020

CLDX institutional ownership history Ownership history
9.9% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 43 47 -8.5%
Opened positions 7 6 +16.7%
Closed positions 11 14 -21.4%
Increased positions 10 11 -9.1%
Reduced positions 9 13 -30.8%
13F shares
 Current Prev Q Change
Total value 5.95M 8.25M -27.8%
Total shares 3.55M 3.55M +0.0%
Total puts 13.4K 13K +3.1%
Total calls 39.3K 30K +31.0%
Total put/call ratio 0.3 0.4 -21.3%
Largest owners
 Shares Value Change
Renaissance Technologies 1.17M $1.94M +4.9%
Vanguard 537.93K $893K +4.2%
Cresset Asset Management 457.67K $760K 0.0%
Dimensional Fund Advisors 345.92K $574K +3.3%
BLK BlackRock 344.48K $572K +0.7%
Acadian Asset Management 298.65K $496K +20.4%
Geode Capital Management 103.98K $172K 0.0%
Bridgeway Capital Management 50.2K $83K -35.1%
CS Credit Suisse 35.32K $58K NEW
NTRS Northern Trust 34.26K $57K -0.9%
Largest transactions
 Shares Bought/sold Change
Renaissance Technologies 1.17M +54.82K +4.9%
Acadian Asset Management 298.65K +50.58K +20.4%
IVZ Invesco 0 -39.39K EXIT
CS Credit Suisse 35.32K +35.32K NEW
Susquehanna International 33.16K -28.55K -46.3%
Bridgeway Capital Management 50.2K -27.1K -35.1%
Stratos Wealth Partners 0 -25K EXIT
Vanguard 537.93K +21.81K +4.2%
A.R.T. Advisors 0 -21.54K EXIT
WINTON 12.03K -20K -62.4%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Immunomedics • AstraZeneca • Roche • Nektar Therapeutics • Novartis • Stemline Therapeutics • Arrogene • Heat Biologics • Tesaro
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: abandoned, abandonment, adenocarcinoma, alsoNote, announced, anthony, ASC, behalf, China, CINDU, context, costimulation, couple, customer, declared, disagreement, doubt, driven, duly, economy, effort, enable, endedMarch, exhibit, expenditure, foreseeable, Furnished, Gilead, global, globally, halt, Health, herewith, HIV, implemented, index, instance, judgment, label, letter, Linkbase, linking, marucci, merger, merit, mitigating, notifying, ordinary, outbreak, pandemic, parental, pathway, platform, preventing, prolonged, rationale, registrant, satisfaction, Schema, scratching, service, shipping, spread, strain, subvert, successful, surfaced, Taxonomy, thereunto, Transaction, travel, undersigned, viability, world, Wuhan, XBRL, York
Removed: AACR, American, Amgen, applied, apply, approved, arise, arm, assessment, attack, August, Australia, beginning, biopsy, BMS, Board, Bone, borrowing, BRAF, cascade, classification, cold, combined, conducted, defend, Depending, diagnosed, discontinuation, effected, EGFR, eliminate, enhanced, European, exceeded, exercised, expectation, expired, expressing, expression, extend, fatigue, February, feet, fifteen, Final, Flow, Fremont, frequent, Frontier, function, gain, Glemba, goodwill, Hampton, headcount, hematologic, Herceptin, hold, immunologic, impacted, implicit, inception, incremental, induced, inhibited, inhibition, initial, Initiative, International, interval, investigational, journal, leased, leasing, malignant, Marrow, Mechanistic, method, minimum, mobilize, modified, modify, nausea, nivolumab, oncology, Opdivo, opportunity, ovarian, package, paired, par, patent, permissive, permitted, person, phosphorylated, pipeline, portion, practical, preliminary, premium, prepaid, published, qualitative, quantitative, radiation, reclassifying, reduced, reduction, registering, regulation, renew, require, resection, respond, restatement, retroactively, retrospective, retrospectively, reverse, select, separately, space, split, square, Squibb, stimulating, suggested, surgery, Tafinlar, Tarceva, terminate, termination, tested, TIL, transition, Transplantation, trended, updated, Vaccine, variable, varlilumab, vitro, vivo, xenograft, Zelboraf
From filing 10-Q 2020 Q1

Financial reports

View all
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
26 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
7 Mar 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-Q
2018 Q2
Quarterly report
8 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
7 Mar 18

Current reports

View all
8-K
Departure of Directors or Certain Officers
18 Jun 20
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
17 Jun 20
8-K
Other Events
15 Jun 20
8-K
Other Events
12 Jun 20
8-K
Celldex Provides Corporate Update and Reports First Quarter 2020 Results
6 May 20
8-K
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
26 Mar 20
8-K
Celldex Provides Corporate Update and Reports Third Quarter 2019 Results
12 Nov 19
8-K
Celldex Provides Corporate Update and Reports Second Quarter 2019 Results
7 Aug 19
8-K
Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer
24 Jun 19
8-K
Departure of Directors or Certain Officers
20 Jun 19

Registration and prospectus

View all
S-8
Registration of securities for employees
26 Jun 20
424B5
Prospectus supplement for primary offering
17 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
12 Jun 20
S-3/A
Shelf registration (amended)
12 Jun 20
424B5
Prospectus supplement for primary offering
27 Mar 20
S-3
Shelf registration
6 Dec 19
S-8
Registration of securities for employees
21 Jun 19
S-8
Registration of securities for employees
21 Jun 19

Proxies

View all
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
7 May 19
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
19 Apr 18
DEF 14A
Definitive proxy
28 Apr 17
PRE 14A
Preliminary proxy
17 Apr 17
DEF 14A
Definitive proxy
21 Apr 16
DEF 14A
Definitive proxy
23 Apr 15
DEF 14A
Definitive proxy
9 Apr 14

Other

View all
EFFECT
Notice of effectiveness
15 Jun 20
CT ORDER
Confidential treatment order
20 Apr 18
EFFECT
Notice of effectiveness
13 Feb 17
EFFECT
Notice of effectiveness
13 Feb 17
CORRESP
Correspondence with SEC
9 Feb 17
CORRESP
Correspondence with SEC
9 Feb 17
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
12 Jan 17
UPLOAD
Letter from SEC
5 Jan 17
CORRESP
Correspondence with SEC
4 Jan 17

Ownership

View all
SC 13G
Celldex Therapeutics / BIOTECHNOLOGY VALUE FUND L P ownership change
26 Jun 20
SC 13G
Celldex Therapeutics / RTW INVESTMENTS ownership change
19 Jun 20
4
Celldex Therapeutics / Samuel Bates Martin ownership change
19 Jun 20
4
Celldex Therapeutics / Margo Heath-Chiozzi ownership change
19 Jun 20
4
Celldex Therapeutics / Sarah Cavanaugh ownership change
19 Jun 20
4
Celldex Therapeutics / Elizabeth Crowley ownership change
19 Jun 20
4
Celldex Therapeutics / RONALD PEPIN ownership change
19 Jun 20
4
Celldex Therapeutics / Richard M. Wright ownership change
19 Jun 20
4
Celldex Therapeutics / Diane C. Young ownership change
19 Jun 20
4
Celldex Therapeutics / TIBOR KELER ownership change
19 Jun 20

Patents

View all
GRANT
Utility
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
2 Jun 20
This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.
APP
Utility
Anti-ALK Antibodies and Methods for Use Thereof
21 May 20
Provided herein are compositions, methods and uses involving antibodies that specifically bind to ALK, a receptor tyrosine kinase, and modulate the expression and/or activity of ALK.
GRANT
Utility
Agonistic antibodies that bind CD40
28 Apr 20
Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed.
APP
Utility
ANTI-CD27 and ANTI-PD-L1 Antibodies and Bispecific Constructs
9 Apr 20
Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain.
APP
Utility
Use of ANTI-PD-1 Antibody In Combination with ANTI-CD27 Antibody In Cancer Treatment
23 Jan 20
This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.